Immunomodulation of the Induction Phase of Lymphokine-Activated Killer Activity by Acute Phase Proteins

Effective treatment of head and neck cancer with biologic response modifiers may be benefitted by an understanding of in vivo factors capable of modulating the lymphokine-activated killer (LAK) cell phenomenon. Eighteen patients with squamous cell carcinoma of the head and neck were studied. Killer...

Full description

Saved in:
Bibliographic Details
Published in:Otolaryngology-head and neck surgery 1991-07, Vol.105 (1), p.26-34
Main Authors: Clayman, Gary L., Liu, Frank J., Taylor, Dorothy L., Savage, Howard E., Lavedan, Pierre, Buchsbaum, Robert M., Trujillo, Jose M., Schantz, Stimson P.
Format: Article
Language:English
Subjects:
Acute-Phase Proteins - analysis
Acute-Phase Proteins - pharmacology
Adult
Aged
Aged, 80 and over
alpha 1-Antitrypsin - analysis
alpha-Macroglobulins - analysis
C-Reactive Protein - analysis
Carcinoma, Squamous Cell - blood
Carcinoma, Squamous Cell - immunology
Cell Line
Complement C3 - analysis
Cytotoxicity, Immunologic
Dose-Response Relationship, Immunologic
Female
Fibrinogen - analysis
Haptoglobins - analysis
Head and Neck Neoplasms - blood
Head and Neck Neoplasms - immunology
Humans
Interleukin-2 - pharmacology
Killer Cells, Lymphokine-Activated - immunology
Lymphocyte Activation
Male
Middle Aged
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Effective treatment of head and neck cancer with biologic response modifiers may be benefitted by an understanding of in vivo factors capable of modulating the lymphokine-activated killer (LAK) cell phenomenon. Eighteen patients with squamous cell carcinoma of the head and neck were studied. Killer cells from each patient, activated by recombinant interleukin-2 (10 U/ml), were induced in either complete medium alone or complete medium plus 10% autologous serum solution and analyzed. Cytotoxicity against both K562 and squamous cell carcinoma (MDA686-Ln) cell lines was determined by use of standard chromium-release assays. The immunomodulatory capacity of serum was correlated with levels of various acute phase proteins. Autologous serum significantly inhibited the induction phase of the LAK phenomenon in 61% of patients and stimulated it in 22%. No patients with early stage I or II disease had significant inhibition of induction. No direct correlation between inhibition and serum acute phase protein levels were seen. An inverse relationship was seen between the C, component of complement and induction inhibition (r = −0.6). These findings suggest that advances of in vivo immunomodulatory therapy will require elucidation of mechanisms of serologic inhibition of the induction phase of the LAK phenomenon. Such studies may lead to serologic modification to enhance treatment efficacy of biologic response modifiers.
ISSN:0194-5998
1097-6817
DOI:10.1177/019459989110500104